文献速递心外重症与机械循环支持

使用COVID-19阳性供体进行心脏移植及其相关短期结局

Utilization of COVID-19 positive donors for Heart transplantation and associated short-term outcomes.
PubMed 文献 · J Heart Lung Transplant · 2022-12-11

该研究纳入2020年4月21日至2022年3月31日美国所有成人潜在供体和心脏移植受者,比较COVID-19阳性与阴性供体的使用情况及移植后结局。结果显示COVID-19阳性供体心脏使用率较低(19.3% vs 26.7%),但移植后90天主要复合终点无显著差异(5.4% vs 5.6%)。作者认为经过仔细选择的COVID-19阳性供体可用于心脏移植,短期结局无差异。

要点

  • COVID-19阳性供体心脏使用率为19.3%,低于阴性供体的26.7%(p<0.001)。
  • 移植后90天死亡、移植物失败和再移植复合终点在阳性与阴性供体组间无显著差异(5.4% vs 5.6%,p=0.91)。
  • 在COVID-19阳性供体中,移植前出现后续阴性检测结果与移植后结局无关。

核心结论

  • 研究结果提示,经过仔细选择的COVID-19阳性供体可用于心脏移植,移植后短期结局无差异。
  • 需要收集关于供体和受者治疗及疫苗接种影响的更多数据,以更好地指导COVID阳性供体器官的使用。

研究设计与样本

  • 研究纳入2020年4月21日至2022年3月31日美国所有成人(≥18岁)潜在供体和心脏移植受者。
  • 供体COVID-19状态定义为器官获取前21天内任何检测阳性(或阴性)。
  • 按供体COVID-19状态比较供体和受者特征及移植后结局,主要复合终点为死亡、移植物失败和再移植。

主要发现

  • 967例COVID-19阳性潜在供体中,19.3%(n=187)用于心脏移植,而COVID-19阴性供体中为26.7%(n=6277),p<0.001。
  • 用于移植的COVID-19阳性供体较阴性供体更年轻,其他特征相似。
  • 接受COVID-19阳性供体心脏的受者移植前使用正性肌力药物的比例较低(24.1% vs 31.7%,p=0.023),使用心室辅助装置的比例也较低(29.7% vs 36.8%,p=0.040)。
  • 按供体COVID-19状态,移植后任何结局均无显著差异,包括90天主要复合终点(5.4% vs 5.6%,p=0.91)。
  • 在COVID-19阳性供体中,移植前出现后续阴性检测与移植后结局无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of using COVID-19 positive donors in heart transplantation (HT) are increasingly relevant, but not well established. The present study evaluated the characteristics and utilization of such donors and associated post-HT outcomes. METHODS: All adult (≥18 years old) potential donors and HT recipients in the United States from April 21, 2020 to March 31, 2022 were included. Donor COVID-19 status was defined by the presence (or absence) of any positive test within 21 days of organ recovery. Donor and recipient characteristics and post-HT outcomes, including a primary composite of death, graft failure, and re-transplantation, were compared by donor COVID-19 status. RESULTS: Of 967 COVID-19(+) potential donors, 19.3% (n = 187) were used for HT compared to 26.7% (n = 6277) of COVID-19(-) donors (p < 0.001). Transplanted COVID-19(+) vs COVID-19(-) donors were younger, but otherwise were similar. Recipients of hearts from COVID-19+ vs COVID-19(-) donors less frequently received pre-HT inotropes (24.1% vs 31.7%, p = 0.023) and ventricular assist device therapy (29.7% vs 36.8%, p = 0.040). There were no significant differences in any post-HT outcome by donor COVID-19 status, including the primary composite outcome at 90 days (5.4% vs 5.6%, p = 0.91). Among COVID-19(+) donors, the presence of a subsequent negative test prior to transplant was not associated with posttransplant outcomes. CONCLUSIONS: Our results suggest that carefully selected COVID-19 positive donors may be used for HT with no difference in short-term post-transplant outcomes. Additional data regarding donor and recipient treatments and impact of vaccination should be collected to better inform our use of organs from COVID(+) donors.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. DeFilippis EM, Wayda B, Lala A, et al. Utilization of COVID-19 positive donors for Heart transplantation and associated short-term outcomes. J Heart Lung Transplant. 2022. PMID: 36609092. doi:10.1016/j.healun.2022.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。